Search results
Jan 22, 2018 · Juno is a pioneer in the development of CAR (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics with a broad, novel portfolio evaluating multiple targets and cancer indications.
Jan 22, 2018 · Juno Therapeutics, the Seattle-based biotech company making cutting-edge cancer immunotherapy treatments, has reached a deal to be acquired by New Jersey-based Celgene for $9 billion, or $87 per ...
Nov 1, 2017 · Shares in Juno Therapeutics jumped by more than 8 per cent on Wednesday after the release of clinical trial data ahead of a closely-watched medical meeting this weekend. The Seattle-based biotech ...
Jan 22, 2018 · Celgene has announced plans to acquire Juno Therapeutics, which is the developer of the chimeric antigen receptor (CAR) T-cell therapy liso-cel (lisocabtagene maraleucel; JCAR017), for $87 per ...
Dec 6, 2013 · Dr. Sadelain and two other Memorial Sloan Kettering researchers – Renier Brentjens, Director of Cellular Therapeutics, and Isabelle Rivière, Director of the Cell Therapy and Cell Engineering Facility – are playing a critical role in the formation of Juno and are founding scientists of the company. (All three researchers will continue in ...
Aug 26, 2021 · JUNO THERAPEUTICS, INC. v. KITE PHARMA, INC. 5 binds the CD19 antigen, a -zeta CD3chain portion, and a costimulatory signaling region. J.A. 58; see also Kite Br. 11; J.A. 383–96 (Complaint). Juno sued Kite, alleging infringem ent of various claims of the ’190 patent through the use, sale, offer for sale, or importation of YESCARTA ®
A high-level overview of Juno Therapeutics (JUNO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
